Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Trial Using 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy for Oligo-Progressive Solid Tumors

NCT05728372 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05728372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05728372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Trial Using 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy for Oligo-Progressive Solid Tumors
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Withdrawn
Start date
August 25, 2023
Completion date
November 8, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant solid neoplasm